The gastrointestinal effects amongst Ehlers-Danlos syndrome, mast cell activation syndrome and postural orthostatic tachycardia syndrome

Sammi Wong; Sara Hasan; Christina Parducci; Bernadette Ann Riley; Sammi Wong; Sara Hasan; Christina Parducci; Bernadette Ann Riley

doi:10.3934/Allergy.2022004

AIMS Allergy and Immunology

2022, Volume 6, Issue 2: 19-24. doi: 10.3934/Allergy.2022004

Previous Article Next Article

Review

The gastrointestinal effects amongst Ehlers-Danlos syndrome, mast cell activation syndrome and postural orthostatic tachycardia syndrome

1.
NYIT College of Osteopathic Medicine, Glen Head, NY, USA
2.
Associate Professor of Family Medicine, Director of Ehlers Danlos Syndrome/Hypermobility Treatment Center at NYIT College of Osteopathic Medicine, Glen Head, NY, USA

Received: 23 November 2021 Revised: 13 March 2022 Accepted: 31 March 2022 Published: 07 April 2022

Ehlers-Danlos syndrome (EDS), mast cell activation syndrome, and postural orthostatic tachycardia syndrome are a triad of comorbid conditions that can occur simultaneously in many patients. Specifically, Ehlers-Danlos syndrome is a group of inherited connective tissue disorders that weakens the connective tissue and causes easy bruising. Mast cell activation syndrome (MCAS) is a condition in the connective tissue of vascularized organs that causes recurrent episodes of anaphylactic symptoms. The irregular activation of mast cells may contribute to immunological manifestations in EDS patients. Postural orthostatic tachycardia syndrome (POTS) is an autonomic nervous system disorder characterized by orthostatic intolerance. Review of the literature suggests an overlap of gastrointestinal (GI) symptoms such as nausea and abdominal pain, hernias, perforations, and more. Thus, this paper will delineate each condition's distinct gastrointestinal symptoms and explore similar gastrointestinal relationships among these conditions.
- Ehlers-Danlos syndrome,
- mast cell activation syndrome,
- postural orthostatic tachycardia syndrome,
- gastrointestinal,
- autoimmune diseases
Citation: Sammi Wong, Sara Hasan, Christina Parducci, Bernadette Ann Riley. The gastrointestinal effects amongst Ehlers-Danlos syndrome, mast cell activation syndrome and postural orthostatic tachycardia syndrome[J]. AIMS Allergy and Immunology, 2022, 6(2): 19-24. doi: 10.3934/Allergy.2022004

Related Papers:

Abstract

Ehlers-Danlos syndrome (EDS), mast cell activation syndrome, and postural orthostatic tachycardia syndrome are a triad of comorbid conditions that can occur simultaneously in many patients. Specifically, Ehlers-Danlos syndrome is a group of inherited connective tissue disorders that weakens the connective tissue and causes easy bruising. Mast cell activation syndrome (MCAS) is a condition in the connective tissue of vascularized organs that causes recurrent episodes of anaphylactic symptoms. The irregular activation of mast cells may contribute to immunological manifestations in EDS patients. Postural orthostatic tachycardia syndrome (POTS) is an autonomic nervous system disorder characterized by orthostatic intolerance. Review of the literature suggests an overlap of gastrointestinal (GI) symptoms such as nausea and abdominal pain, hernias, perforations, and more. Thus, this paper will delineate each condition's distinct gastrointestinal symptoms and explore similar gastrointestinal relationships among these conditions.

Conflict of interest

All authors declare no conflicts of interest in this paper.

References

[1]	Rao JN, Wang JY (2010) Intestinal architecture and development. Regulation of Gastrointestinal Mucosal Growth. San Rafael: Morgan & Claypool Life Sciences: 3-8.
[2]	Shahrestani J, Das JM (2020) Neuroanatomy, Auerbach Plexus. Treasure Island: StatPearls Publishing.
[3]	Ramsay DB, Stephen S, Borum M, et al. (2010) Mast cells in gastrointestinal disease. Gastroenterol Hepatol 6: 772-777.
[4]	Akin C (2015) Mast cell activation syndromes presenting as anaphylaxis. Immunol Allergy Clin 35: 277-285. https://doi.org/10.1016/j.iac.2015.01.010
[5]	Malfait F, Francomano C, Byers P, et al. (2017) The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C 175: 8-26. https://doi.org/10.1002/ajmg.c.31552
[6]	Nelson AD, Mouchli MA, Valentin N, et al. (2015) Ehlers Danlos syndrome and gastrointestinal manifestations: a 20-year experience at Mayo Clinic. Neurogastroenterol Motil 27: 1657-1666. https://doi.org/10.1111/nmo.12665
[7]	Fikree A, Chelimsky G, Collins H, et al. (2017) Gastrointestinal involvement in the Ehlers-Danlos syndromes. Am J Med Genet C 175: 181-187. https://doi.org/10.1002/ajmg.c.31546
[8]	Alomari M, Hitawala A, Chadalavada P, et al. (2020) Prevalence and predictors of gastrointestinal dysmotility in patients with hypermobile Ehlers-Danlos syndrome: a tertiary care center experience. Cureus 12: e7881. https://doi.org/10.7759/cureus.7881
[9]	Hakim AJ, Grahame R (2004) Non-musculoskeletal symptoms in joint hypermobility syndrome. Indirect evidence for autonomic dysfunction?. Rheumatology 43: 1194-1195. https://doi.org/10.1093/rheumatology/keh279
[10]	El Masri H, Loong TH, Meurette G, et al. (2018) Bowel perforation in type IV vascular Ehlers-Danlos syndrome. A systematic review. Tech Coloproctology 22: 333-341. https://doi.org/10.1007/s10151-018-1783-4
[11]	Freeman RK, Swegle J, Sise MJ (1996) The surgical complications of Ehlers-Danlos syndrome. Am Surg 62: 869-873.
[12]	Frieri M (2018) Mast cell activation syndrome. Clin Rev Allerg Immu 54: 353-365. https://doi.org/10.1007/s12016-015-8487-6
[13]	Ravi A, Butterfield J, Weiler CR (2014) Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α. J Allergy Clin Immunol Pract 2: 775-778. https://doi.org/10.1016/j.jaip.2014.06.011
[14]	Valent P (2013) Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res 3: 159-172.
[15]	Weinstock LB, Rezaie A, Brook JB, et al. (2020) Small intestinal bacterial overgrowth is common in mast cell activation syndrome. J Med Clin Res Rev 4: 1-13. https://doi.org/10.33425/2639-944X.1170
[16]	Jackson CW, Pratt CM, Rupprecht CP, et al. (2021) Mastocytosis and mast cell activation disorders: Clearing the air. Int J Mol Sci 22: 11270. https://doi.org/10.3390/ijms222011270
[17]	Gilfillan AM, Beaven MA (2011) Regulation of mast cell responses in health and disease. Crit Rev Immunol 31: 475-529. https://doi.org/10.1615/CritRevImmunol.v31.i6.30
[18]	Mehr SE, Barbul A, Shibao CA (2018) Gastrointestinal symptoms in postural tachycardia syndrome: a systematic review. Clin Auton Res 28: 411-421. https://doi.org/10.1007/s10286-018-0519-x
[19]	Wang LB, Culbertson CJ, Deb A, et al. (2015) Gastrointestinal dysfunction in postural tachycardia syndrome. J Neurol Sci 359: 193-196. https://doi.org/10.1016/j.jns.2015.10.052
[20]	Nayagam JS, Sagar VA, Asante M (2019) Managing gastrointestinal manifestations in patients with pots: a UK DGH experience. Br J Cardiol 26: 101-104.
[21]	Lawal A, Barboi A, Krasnow A, et al. (2007) Rapid gastric emptying is more common than gastroparesis in patients with autonomic dysfunction. Am J Gastroenterol 102: 618-623. https://doi.org/10.1111/j.1572-0241.2006.00946.x
[22]	Zhao S, Tran VH (2022) Postural Orthostatic Tachycardia Syndrome. Treasure Island: StatPearls Publishing.
[23]	Gunning WT, Kvale H, Kramer PM, et al. (2019) Postural orthostatic tachycardia syndrome is associated with elevated G-protein coupled receptor autoantibodies. J Am Heart Assoc 8: e013602. https://doi.org/10.1161/JAHA.119.013602

Reader Comments

Your name:*

Email:*
© 2022 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)